Anna Vassall PhD

Professor of Health Economics


Anna Vassall is a health economist with over twenty five years of experience in economic analysis in low and middle income countries. Her first degree is in economics. She then worked in the NHS supporting funding/contracting. She then took an MSc in Health Planning and Financing at the LSHTM, thereafter working for DFID as a health economist in the UK and Pakistan. This was followed by a period at Royal Tropical Institute (KIT) Amsterdam working on health planning and financing, aid effectiveness and the cost-effectiveness of tuberculosis and reproductive health in a wide range of low and middle income countries. Thereafter she directed and provided economic support to European Community and World Bank funded health sector reform and development projects in Yemen, East Timor, Syria and Sudan. Her PhD is in the economic evaluation of tuberculosis control.

She has worked at LSHTM since 2010  specialising on the economics of HIV, sexual and reproductive health, gender based violence prevention and tuberculosis. She has an interest in incorporating a health systems perspective into economic evaluation and priority setting methods. She currently leads the economic evaluation and priority setting group in the Department of Global Health and Development. She is lead member of the TB-MAC modelling consortium and sits on the Strategic and Technical Advisory Group for the WHO's Global Tuberculosis Programme (STAG-TB).






Her current research interest is the public choice, priority setting and economic evaluation for HIV, TB and Sexual Reproductive Health. She has a keen interest in 'real world' evaluation methods and incorporating a broader health systems perspective in economic analysis. She has also published on health services financing, in particular the role of development assistance for health. 

Anna is a member of the Social and Mathematical Epidemiology Group, within Global Health and Development.

Research areas

  • Complex interventions
  • Decision analysis
  • Diagnostics
  • Economic evaluation
  • Equity
  • Global Health
  • Health care financing
  • Health systems
  • Health technology assessment
  • Infectious disease policy
  • Modelling
  • Reproductive health
  • Research : policy relationship
  • Sexual health


  • Development studies

Disease and Health Conditions

  • Mental health
  • Non-communicable diseases
  • Sexually transmitted infection
  • Tuberculosis


  • Arab World
  • East Asia & Pacific (developing only)
  • Europe & Central Asia (developing only)
  • Least developed countries: UN classification
  • Middle East & North Africa (developing only)
  • Pacific island small states
  • South Asia
  • Sub-Saharan Africa (developing only)


  • Bangladesh
  • Bolivia
  • Brazil
  • China
  • Egypt, Arab Rep.
  • Ethiopia
  • Ghana
  • India
  • Kenya
  • Malawi
  • Mozambique
  • Nepal
  • Pakistan
  • Peru
  • South Africa
  • South Sudan
  • Sudan
  • Swaziland
  • Tanzania
  • Timor-Leste
  • Uganda
  • Ukraine
  • Vietnam
  • Yemen, Rep.
  • Zambia

Other interests

  • Aid Effectiveness
  • Antimicrobial Resistance
  • Cluster Randomised Trials
  • Co-morbidities
  • Community Health Workers
  • Cost Effectiveness Analysis
  • Development Finance
  • Fragile States
  • Multi-drug resistant Tuberculosis
  • Multisectoral Responses To HIV
  • Poverty measurement
  • TB Centre
Back to top